Trimetazidine Therapy in Chronic Coronary Syndrome

Introduction to Trimetazidine

• The European Society of Cardiology recommends trimetazidine as add-on therapy in patients with chronic coronary syndrome who have inadequate symptom control despite treatment with beta-blockers and/or calcium channel blockers, with a Class IIb recommendation (Level B evidence) 1, 2

Current Guideline Position

• The European Society of Cardiology downgraded trimetazidine from its previous position, with long-acting nitrates and ranolazine now receiving preferential Class IIa recommendations over trimetazidine 1, 2
• This represents a downgrade from the 2019 guidelines, which gave trimetazidine a Class IIa recommendation as second-line treatment 1

Treatment Algorithm

• Beta-blockers and/or calcium channel blockers remain the foundation of antianginal treatment, according to the European Society of Cardiology 3, 4, 5
• Short-acting nitroglycerin is recommended for acute symptom relief in all patients, as per the European Society of Cardiology guidelines 3, 4

When to Add Trimetazidine

• Add trimetazidine when there is inadequate symptom control on optimized doses of beta-blockers and/or calcium channel blockers, as recommended by the European Society of Cardiology 1, 2, 6
• Trimetazidine may be considered in patients with contraindications or intolerance to first-line agents (beta-blockers, calcium channel blockers), according to the European Society of Cardiology guidelines 3, 4, 6

Specific Clinical Scenarios Favoring Trimetazidine

• Trimetazidine is preferred in patients with low blood pressure because it does not exert hemodynamic effects, as stated by the European Society of Cardiology 8, 6
• Trimetazidine improves metabolic efficiency without affecting oxygen demand, unlike beta-blockers, calcium channel blockers, and nitrates, according to the European Society of Cardiology 4, 8, 6

Important Contraindications and Precautions

• The European Society of Cardiology lists Parkinson's disease, parkinsonism, and related movement disorders as absolute contraindications for trimetazidine 8, 6, 7, 9
• Severe renal impairment (creatinine clearance <30 ml/min) is also an absolute contraindication, as per the European Society of Cardiology guidelines 8, 6, 7, 9

Clinical Efficacy Evidence

• No relevant evidence is available in this section that is not marked as [ignore ref]

Common Pitfalls to Avoid

• The European Society of Cardiology advises against using trimetazidine as first-line monotherapy when beta-blockers or calcium channel blockers are appropriate and tolerated 1, 2
• Screening for movement disorders is recommended before initiating trimetazidine therapy, as per the European Society of Cardiology guidelines 8, 6, 7
• Checking renal function is necessary before prescribing trimetazidine, according to the European Society of Cardiology 8, 6, 7
• Ranolazine may be considered instead of trimetazidine in diabetic patients for dual benefits on angina and glycemic control, as stated by the European Society of Cardiology 8, 9